Best Medical Stocks To Keep An Eye On – April 27th

UnitedHealth Group, Eli Lilly and Company, Merck & Co., Inc., AbbVie, and Gilead Sciences are the five Medical stocks to watch today, according to MarketBeat’s stock screener tool. Error: Response status code does not indicate success: 429 (Too Many Requests). These companies had the highest dollar trading volume of any Medical stocks within the last several days.

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

UNH stock traded down $6.05 during midday trading on Friday, hitting $418.20. The company’s stock had a trading volume of 9,255,934 shares, compared to its average volume of 4,482,211. The company’s fifty day moving average price is $503.28 and its 200 day moving average price is $534.62. UnitedHealth Group has a twelve month low of $412.02 and a twelve month high of $630.73. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.83 and a quick ratio of 0.91. The stock has a market capitalization of $380.66 billion, a P/E ratio of 26.98, a PEG ratio of 1.37 and a beta of 0.61.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE:LLY traded up $25.21 during trading on Friday, hitting $884.94. 3,395,903 shares of the company were exchanged, compared to its average volume of 3,444,748. The stock has a market cap of $839.07 billion, a price-to-earnings ratio of 75.57, a P/E/G ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm has a fifty day moving average price of $827.69 and a two-hundred day moving average price of $817.91. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00.

Merck & Co., Inc. (MRK)

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Shares of MRK stock traded up $2.99 on Friday, reaching $82.83. The stock had a trading volume of 28,374,477 shares, compared to its average volume of 11,908,288. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79. Merck & Co., Inc. has a 12 month low of $75.93 and a 12 month high of $134.63. The firm’s 50-day moving average is $87.05 and its two-hundred day moving average is $95.13. The firm has a market capitalization of $208.88 billion, a price-to-earnings ratio of 12.31, a P/E/G ratio of 0.77 and a beta of 0.40.

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Shares of NYSE:ABBV traded up $5.59 on Friday, hitting $185.96. The company had a trading volume of 10,480,961 shares, compared to its average volume of 6,045,510. The stock has a market cap of $328.96 billion, a price-to-earnings ratio of 77.48, a P/E/G ratio of 1.62 and a beta of 0.55. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94. AbbVie has a 1-year low of $153.58 and a 1-year high of $218.66. The stock has a 50 day moving average price of $196.85 and a 200 day moving average price of $187.18.

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Shares of NASDAQ:GILD traded down $2.98 during trading on Friday, reaching $103.17. 14,207,970 shares of the stock were exchanged, compared to its average volume of 7,506,787. The stock has a 50-day moving average price of $109.21 and a 200-day moving average price of $98.24. The firm has a market cap of $128.46 billion, a PE ratio of 278.84, a PEG ratio of 0.71 and a beta of 0.32. Gilead Sciences has a 12 month low of $62.07 and a 12 month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.